Lung Tumour Markers in Oncology Practice
Author Information
Author(s): G Buccheri, D Ferrigno
Primary Institution: Divisione di Pneumologia, Ospedale ‘S. Croce e Carle’, Cuneo, Italy
Hypothesis
This study aims to compare the effectiveness of tissue polypeptide antigen (TPA) and CA 125 tumour associated antigen in lung cancer diagnosis and prognosis.
Conclusion
Both TPA and CA 125 are effective markers for evaluating lung cancer and predicting patient outcomes.
Supporting Evidence
- Both TPA and CA 125 correlated significantly with the T, N, and M stage descriptors at diagnosis.
- CA 125 was strongly predictive of pleural neoplastic involvement.
- Univariate analysis showed that elevated levels of both markers were associated with worse prognosis.
Takeaway
Doctors can use two blood tests, TPA and CA 125, to help understand how serious lung cancer is and how well treatment is working.
Methodology
The study involved 384 lung cancer patients, measuring TPA and CA 125 levels before and after treatment, and correlating these with disease stage and patient outcomes.
Potential Biases
There may be biases related to the selection of patients and the interpretation of results.
Limitations
The study may not account for all potential confounding factors affecting the results.
Participant Demographics
The study included 384 new lung cancer patients, with 309 males.
Statistical Information
P-Value
<0.001
Confidence Interval
95% confidence interval: 0.695–0.801
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website